NASDAQ:ARTLArtelo Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Artelo Biosciences Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.30 +0.09 (+7.44 %) (As of 05/22/2020 04:00 PM ET) Add Compare Share Today's Range$1.18Now: $1.30▼$1.3050-Day Range$0.82MA: $1.14▼$1.3852-Week Range$0.61Now: $1.30▼$9.00Volume51,698 shsAverage Volume63,424 shsMarket Capitalization$4.46 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Artelo Biosciences, Inc., an ethical biopharmaceutical company, focuses on developing, licensing, and commercializing cannabinoid therapeutic treatments. Its products pipeline includes ART12.11, a cannabidiol composition for the treatment of inflammatory bowel disease, stroke, and rare/orphan diseases; ART26.12, an endocannabinoid transport protein (FABP5) inhibitor for the treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain; and ART27.13 for the treatment of cancer and cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is based in La Jolla, California.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingArtelo Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Artelo Biosciences has a potential upside of 515.4% from its current price of $1.30.Amount of Analyst CoverageArtelo Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesArtelo Biosciences has received 20 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArtelo Biosciences has received 19 “underperform” votes. (Add your “underperform” vote.)Community SentimentArtelo Biosciences has received 51.28% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Artelo Biosciences and other stocks. Vote “Outperform” if you believe ARTL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARTL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArtelo Biosciences does not currently pay a dividend.Dividend GrowthArtelo Biosciences does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artelo Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $63,333.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 12.78% of the stock of Artelo Biosciences is held by insiders.Percentage Held by InstitutionsOnly 0.44% of the stock of Artelo Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Artelo Biosciences is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artelo Biosciences is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtelo Biosciences has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.85 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Business services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARTL Previous Symbol CUSIPN/A CIKN/A Webwww.artelobio.com Phone760-943-1689Debt Debt-to-Equity RatioN/A Current Ratio4.75 Quick Ratio4.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.60 per share Price / Book0.81Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-2,170,000.00 Net MarginsN/A Return on Equity-123.65% Return on Assets-101.75%Miscellaneous Employees1 Outstanding Shares3,430,000Market Cap$4.46 million Next Earnings Date7/20/2020 (Estimated) OptionableNot Optionable NASDAQ:ARTL Rates by TradingView Receive ARTL News and Ratings via Email Sign-up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Artelo Biosciences (NASDAQ:ARTL) Frequently Asked Questions How has Artelo Biosciences' stock been impacted by COVID-19 (Coronavirus)? Artelo Biosciences' stock was trading at $1.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARTL shares have increased by 28.7% and is now trading at $1.30. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Artelo Biosciences? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Artelo Biosciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Artelo Biosciences. When is Artelo Biosciences' next earnings date? Artelo Biosciences is scheduled to release its next quarterly earnings announcement on Monday, July 20th 2020. View our earnings forecast for Artelo Biosciences. How were Artelo Biosciences' earnings last quarter? Artelo Biosciences (NASDAQ:ARTL) released its quarterly earnings results on Tuesday, April, 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.13. View Artelo Biosciences' earnings history. What price target have analysts set for ARTL? 1 brokerages have issued twelve-month price targets for Artelo Biosciences' stock. Their forecasts range from $8.00 to $8.00. On average, they expect Artelo Biosciences' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 515.4% from the stock's current price. View analysts' price targets for Artelo Biosciences. Has Artelo Biosciences been receiving favorable news coverage? Media stories about ARTL stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Artelo Biosciences earned a media sentiment score of -4.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutArtelo Biosciences. Are investors shorting Artelo Biosciences? Artelo Biosciences saw a increase in short interest in May. As of May 15th, there was short interest totaling 25,200 shares, an increase of 31.9% from the April 30th total of 19,100 shares. Based on an average daily volume of 118,500 shares, the short-interest ratio is presently 0.2 days. Currently, 1.1% of the company's shares are short sold. View Artelo Biosciences' Current Options Chain. Who are some of Artelo Biosciences' key competitors? Some companies that are related to Artelo Biosciences include SPAR Group (SGRP), Protagenic Therapeutics (PTIX), Kingold Jewelry (KGJI), QuoteMedia (QMCI), PeerStream (PEER), SilverSun Technologies (SSNT), Janel (JANL), ITEX (ITEX), China Recycling Energy (CREG), Sito Mobile (SITO), International Monetary Systems (ITNM), Accelerize (ACLZ), China Techfaith Wireless Comm. Tech. (CNTF), CardioGenics (CGNH) and LiveWorld (LVWD). View all competitors. What other stocks do shareholders of Artelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Artelo Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Vaxart (VXRT), Amarin (AMRN), Armata Pharmaceuticals (ARMP), Carnival (CCL), Gilead Sciences (GILD) and QUALCOMM (QCOM). Who are Artelo Biosciences' key executives? Artelo Biosciences' management team includes the following people: Mr. Gregory D. Gorgas, Pres, CEO, CFO, Treasurer, Sec. & Director (Age 56)Mr. Peter Michael O'Brien, Sr. VP of European Operations (Age 41)Dr. Steven D. Reich, Chief Medical Officer (Age 73)Mr. Jason H. Baybutt, Sr. VP of Fin. (Age 47) What is Artelo Biosciences' stock symbol? Artelo Biosciences trades on the NASDAQ under the ticker symbol "ARTL." How do I buy shares of Artelo Biosciences? Shares of ARTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Artelo Biosciences' stock price today? One share of ARTL stock can currently be purchased for approximately $1.30. How big of a company is Artelo Biosciences? Artelo Biosciences has a market capitalization of $4.46 million. Artelo Biosciences employs 1 workers across the globe. What is Artelo Biosciences' official website? The official website for Artelo Biosciences is www.artelobio.com. How can I contact Artelo Biosciences? Artelo Biosciences' mailing address is 888 Prospect Street Suite 210, La Jolla CA, 92037. The company can be reached via phone at 760-943-1689 or via email at [email protected] This page was last updated on 5/24/2020 by MarketBeat.com Staff
